Last reviewed · How we verify
Lasix 25
Lasix (furosemide) is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.
Lasix (furosemide) is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
At a glance
| Generic name | Lasix 25 |
|---|---|
| Sponsor | Heart Care Foundation |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This increases osmotic pressure in the tubular lumen, drawing water into the urine and producing rapid diuresis. The drug is highly potent and commonly used to reduce fluid overload in cardiac and renal conditions.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Empagliflozin in Acute Heart Failure (PHASE4)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- "Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function" (NA)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (PHASE1, PHASE2)
- Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lasix 25 CI brief — competitive landscape report
- Lasix 25 updates RSS · CI watch RSS
- Heart Care Foundation portfolio CI